Insider · CIK 0001820590
Sanjeev Narula
cfoofficer
Files at ITCI (Intra-Cellular Therapies, Inc.), PHAT (Phathom Pharmaceuticals, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 6, 2026 | PHAT Phathom Pharmaceuticals, Inc. | FTax withholding Common Stock | -13,485 | $6.78 | $91k | 214,718 | 4 d ago |
| Jan 2, 2026 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Common Stock | +82,715 | $0.00 | $0 | 226,715 | Jan 2, 2026 |
| Jan 2, 2026 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +42,848 | $0.00 | $0 | 42,848 | Jan 2, 2026 |
| Oct 6, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Common Stock | +144,000 | $0.00 | $0 | 144,000 | Oct 8, 2025 |
| Oct 6, 2025 | PHAT Phathom Pharmaceuticals, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +200,000 | $0.00 | $0 | 200,000 | Oct 7, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Stock Option (right to buy)derivative | -17,251 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -35,046 | - | - | 0 | Apr 2, 2025 |
| Apr 2, 2025 | ITCI Intra-Cellular Therapies, Inc. | DDisposition to issuer Restricted Stock Unitsderivative | -22,727 | - | - | 0 | Apr 2, 2025 |
| Feb 3, 2025 | ITCI Intra-Cellular Therapies, Inc. | AGrant or award Restricted Stock Unitsderivative | +22,727 | $0.00 | $0 | 22,727 | Feb 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.